Overview
- IBRX logged an 11th straight up day on Friday, touching $5.58 intraday and closing up nearly 40% at $5.52 for a new 52-week high.
- Preliminary 2025 revenue reached $113 million for Anktiva, roughly a 700% year-over-year increase, with Q4 at $38.3 million, up 20% sequentially and 431% from a year earlier.
- Saudi Arabia approved Anktiva for metastatic non‑small cell lung cancer, the therapy’s first regulatory clearance outside the U.S., with the company planning local expansion.
- Enrollment in the registrational non‑muscle‑invasive bladder cancer study surpassed 85%, with a BLA submission targeted by the end of 2026.
- An early CD19 CAR‑NK program combined with rituximab reported disease control in four patients, including two durable complete remissions at seven and 15 months, based on a very small cohort.